The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Abstract
Oxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for treatment failure still is the existence of tumor intrinsic or acquired resistance. Consequently, it is important to understand the molecular mechanisms underlying the appearance of this phenomenon to find ways of circumventing it and to improve and optimize treatments. This review will be focused on recent discoveries about oxaliplatin tumor-related resistance mechanisms, including alterations in transport, detoxification, DNA damage response and repair, cell death (apoptotic and nonapoptotic), and epigenetic mechanisms. Mol Cancer Ther; 14(8); 1767–76. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Self-citationEpigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Self-citationRegulated necrosis: the expanding network of non-apoptotic cell death pathways
Berghe, T. V., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., & Vandenabeele, P. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3737 · Cited by 1,735
Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure
Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., & D'Angelica, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0833 · Cited by 1,187
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
Glutathione Transferases and Cancer
Tsuchida, S., & Sato, K. (1992) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239209082566 · Cited by 537
Yang, A. D., Fan, F., Camp, E. R., van Buren, G., Liu, W., Somcio, R., Gray, M. J., Cheng, H., Hoff, P. M., & Ellis, L. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0038 · Cited by 526
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells
Tang, D., Kang, R., Cheh, C.-W., Livesey, K. M., Liang, X., Schapiro, N. E., Benschop, R., Sparvero, L. J., Amoscato, A. A., Tracey, K. J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.261 · Cited by 461
Clinical pharmacokinetics of oxaliplatin: a critical review.
Graham, M. A., Lockwood, G. F., Greenslade, D., Brienza, S., Bayssas, M., & Gamelin, E. (2000) · PubMed · Cited by 455
Cited by
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Wang, L., Cho, K. B., Li, Y., Tao, G., Xie, Z., & Guo, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225758 · Cited by 605
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Recent advances in exosome-mediated nucleic acid delivery for cancer therapy
Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306
Linares, J., Sallent-Aragay, A., Badia-Ramentol, J., Recort-Bascuas, A., Méndez, A., Manero-Rupérez, N., Re, D. L., Rivas, E. I., Guiu, M., Zwick, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36334-1 · Cited by 109
Metadata
- Authors
- Martinez-Balibrea, E., Martínez-Cardús, A., Ginés, A., Ruiz de Porras, V., Moutinho, C., Layos, L., Manzano, J. L., Bugés, C., Bystrup, S., Esteller, M., & Abad, A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2015-08-01
- Volume
- 14
- Issue
- 8
- Pages
- 1767-1776
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2170914411
- Cited by
- 335
- References
- 85
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0636
- The paper
- Martinez-Balibrea, E., Martínez-Cardús, A., Ginés, A., Ruiz de Porras, V., Moutinho, C., Layos, L., Manzano, J. L., Bugés, C., Bystrup, S., Esteller, M., & Abad, A. (2015). Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.